Zoetis
ZTS
$77.34
+3.09%
Zoetis Inc. is a global animal health company that develops, manufactures, and markets pharmaceuticals, vaccines, diagnostics, and other health products for livestock and companion animals, operating within the healthcare sector. As the largest player in the animal health industry, Zoetis holds a dominant market share, with roughly 65% of revenue from companion animals and 35% from production animals, and it was previously Pfizer's animal health unit. The current investor narrative centers on the company's growth trajectory, as recent quarterly results showed mixed performance with an EPS beat but concerns about declining growth in key segments, prompting analysts to question its pathway to growth. Additionally, the stock has experienced a significant drawdown over the past year, raising debates about its competitive positioning and future prospects.…
ZTS
Zoetis
$77.34
Related headlines
Investment Opinion: Should I buy ZTS Today?
We rate Zoetis as a Hold. The stock is currently trading at $77.73, with an average analyst target of $100.63, implying a 29.5% upside. The consensus recommendation is 'Buy', but the recent revenue stagnation and high debt levels warrant caution. The forward PE of 11.69x suggests the market expects earnings growth, but this is not yet reflected in revenue trends.
Sign up to view all
ZTS 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stock's valuation is attractive on a forward basis, but the lack of revenue growth and high debt are concerning. The wide analyst target range reflects uncertainty. If revenue growth accelerates above 5% and the company reduces debt, the stance would upgrade to bullish. Conversely, if revenue declines or margins compress, it would downgrade to bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Zoetis's 12-month outlook, with a consensus price target around $96.00 and implied upside of +24.1% versus the current price.
Average Target
$96.00
0 analysts
Implied Upside
+24.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $155
Analyst target range
The target price range spans from a low of $80.00 to a high of $160.00, with the high target implying a 105.8% upside, likely assuming a full recovery to previous valuation levels, while the low target of $80.00 is only 2.9% above the current price, suggesting some analysts see limited downside. Recent ratings actions show a mix: HSBC, TD Cowen, and Citigroup maintained Buy ratings, while Argus Research downgraded from Buy to Hold in May 2026, and UBS and Barclays have Neutral/Equal Weight stances. The wide spread between high and low targets (100% difference) indicates high uncertainty about Zoetis' growth prospects, particularly given the recent revenue deceleration and competitive pressures.
Bulls vs Bears: ZTS Investment Factors
Zoetis presents a mixed picture: it has a dominant market position, high margins, and strong cash flow, but faces significant challenges including stalled revenue growth, a severe stock decline, and high leverage. The bear case currently has stronger evidence, as the revenue stagnation and negative price momentum are hard to ignore. The most important tension is whether the company can reignite growth in its key segments; if it can, the stock is deeply undervalued, but if not, the current valuation may still be too high. The wide analyst target range ($80-$160) reflects this uncertainty.
Bullish
- Dominant market position in animal health: Zoetis is the largest player in the animal health industry, with a market share that supports pricing power and scale advantages. This leadership position provides a competitive moat that is difficult for smaller rivals to replicate.
- High gross and operating margins: Gross margin stands at 70.5% and operating margin at 38.0%, reflecting strong pricing power and operational efficiency. These margins are among the highest in the healthcare sector, indicating a robust business model.
- Forward PE suggests earnings growth: The forward PE of 11.69x is significantly lower than the trailing PE of 20.87x, implying the market expects substantial earnings growth. Analysts estimate EPS of $9.34 for the next fiscal year, up from trailing EPS of $3.72, a potential 151% increase.
- Analyst consensus is Buy with upside: The average analyst target price is $100.63, representing a 29.5% upside from the current price of $77.73. The consensus recommendation is 'Buy' with a mean score of 2.16, indicating overall positive sentiment.
Bearish
- Revenue growth has stalled: Revenue in Q1 2026 was $2.262 billion, up only 1.89% YoY, and has been flat over the last four quarters (ranging from $2.262B to $2.460B). This stagnation raises concerns about the company's ability to grow.
- Stock is in a severe downtrend: The stock has fallen 50.05% over the past year, from a 52-week high of $158.30 to $77.73, and is trading near its 52-week low of $71.00. This underperformance versus the S&P 500 (+20.48%) highlights significant negative momentum.
- High debt-to-equity ratio: Debt-to-equity is 2.85x, indicating a highly leveraged balance sheet. This increases financial risk, especially if interest rates remain elevated or earnings decline.
- Key segments are declining: Analysts have questioned Zoetis' pathway to growth as key segments like companion animals (63.8% of revenue) are sliding. This suggests that the core business may be losing momentum.
ZTS Technical Analysis
Zoetis is in a pronounced downtrend, with the stock price falling 50.05% over the past year, from a 52-week high of $158.30 to a current price of $77.73, which is near the 52-week low of $71.00. The stock is trading at approximately 7.4% above its 52-week low and 50.9% below its 52-week high, indicating a position deep in the lower end of its range, which often suggests either a value opportunity or a falling knife, depending on fundamental catalysts. The 1-year price change of -50.05% contrasts sharply with the S&P 500's +20.48% gain, highlighting severe underperformance and a relative strength of -70.53% over the same period.
Beta
0.73
0.73x market volatility
Max Drawdown
-54.2%
Largest decline past year
52-Week Range
$71-$156
Price range past year
Annual Return
-50.0%
Cumulative gain past year
| Period | ZTS Return | S&P 500 |
|---|---|---|
| 1m | -0.8% | +5.5% |
| 3m | -0.5% | +1.7% |
| 6m | -41.0% | +12.2% |
| 1y | -50.0% | +18.6% |
| ytd | -38.6% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ZTS Fundamental Analysis
Zoetis' revenue growth has decelerated, with the most recent quarter (Q1 2026) showing revenue of $2.262 billion, up only 1.89% year-over-year, compared to 8.1% growth in Q1 2025 (from $2.220 billion to $2.262 billion). Over the past four quarters, revenue has been relatively flat: Q2 2025 at $2.460 billion, Q3 2025 at $2.400 billion, Q4 2025 at $2.387 billion, and Q1 2026 at $2.262 billion, indicating a stagnation trend. Segment data reveals that companion animal products (Dogs and Cats) generate $1.443 billion, or 63.8% of total revenue, while production animal segments like Cattle ($392 million) and Swine ($123 million) are smaller, and the overall growth is being dragged by these key segments, as noted in recent analyst commentary.
Quarterly Revenue
$2.3B
2026-03
Revenue YoY Growth
+1.9%
YoY Comparison
Gross Margin
71.7%
Latest Quarter
Free Cash Flow
$2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ZTS Overvalued?
Given that Zoetis has positive net income, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 20.87x, while the forward PE is 11.69x, implying that the market expects significant earnings growth, which is consistent with the estimated EPS of $9.34 for the next fiscal year, up from the trailing EPS of $3.72 (calculated from net income of $601 million and shares outstanding of 422.1 million). The gap between trailing and forward PE suggests the market is pricing in a substantial earnings recovery, which may be optimistic given the recent revenue stagnation.
PE
20.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are elevated due to Zoetis' high debt-to-equity ratio of 2.85x, which increases interest expense and financial vulnerability. The company's revenue growth has decelerated to just 1.89% YoY in Q1 2026, and with net income of $601 million, any further decline could pressure earnings. Additionally, the payout ratio of 33.3% indicates a commitment to dividends, which may limit flexibility if cash flows weaken. The current ratio of 3.03 provides some liquidity cushion, but the high leverage remains a concern.
FAQ
The key risks are: 1) Financial risk from high debt-to-equity of 2.85x, which could strain cash flows if interest rates rise. 2) Operational risk from revenue stagnation, with Q1 2026 growth of only 1.89% YoY. 3) Competitive risk from new entrants or generic products in the animal health market. 4) Macro risk from a potential recession reducing pet spending, as companion animals account for 63.8% of revenue. The most severe risk is a continued decline in key segments, which could lead to a further drop in the stock price, potentially to the 52-week low of $71.00, a 8.7% downside from current levels.
The 12-month forecast is uncertain, with a base case target of $100.63 (29.5% upside), a bull case of $160 (105.8% upside), and a bear case of $71 (8.7% downside). The probabilities are 25% bull, 50% base, and 25% bear. The most likely scenario is the base case, where the stock trades around $100, assuming modest growth and stable margins. The key assumption is that revenue growth picks up to at least 2-3% and the company maintains its margins. If growth fails to materialize, the stock could test the 52-week low.
Zoetis is trading at a forward PE of 11.69x, which is below the market average and its own historical average, suggesting it is undervalued if earnings growth materializes. However, the trailing PE of 20.87x is not cheap, and the PEG ratio of 2.04 indicates the stock is expensive relative to its growth rate. The market is pricing in a significant earnings recovery, which may be optimistic given the recent revenue stagnation. Compared to peers, Zoetis' valuation is in line with the sector, but the high debt-to-equity ratio adds risk. Overall, the stock is fairly valued to slightly undervalued on a forward basis, but the lack of growth makes it a value trap risk.
Zoetis is a good buy for investors who believe the company can reignite growth, given the 29.5% upside to the average analyst target of $100.63. However, the stock is in a downtrend and revenue growth is only 1.89% YoY, so it is not without risk. The forward PE of 11.69x is attractive if earnings meet estimates, but the trailing PE of 20.87x suggests the market is not pricing in a permanent decline. For risk-tolerant investors with a 12-month horizon, it could be a contrarian opportunity, but for conservative investors, waiting for signs of growth acceleration is prudent.
Zoetis is more suitable for long-term investment, given its dominant market position and potential for growth recovery. The stock has a beta of 0.73, indicating lower volatility than the market, and pays a dividend yield of 1.59%, providing some income. However, the recent 50% decline suggests high short-term risk, and the revenue stagnation makes it less attractive for short-term trading. A minimum holding period of 3-5 years is recommended to allow for a potential turnaround. For short-term traders, the stock is in a downtrend, so it is not ideal unless there is a clear catalyst.